(Q33408918)

26 July 2017

title

A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors (English)

1 reference

26 July 2017

Lian Liu

1

1 reference

26 July 2017

Wen Zhang

2

1 reference

26 July 2017

Wenhua Li

3

1 reference

26 July 2017

Fangfang Lv

4

1 reference

26 July 2017

Zuguang Xia

5

1 reference

26 July 2017

Sheng Zhang

6

1 reference

26 July 2017

Wen Liu

7

1 reference

26 July 2017

Anthe S Zandvliet

8

1 reference

26 July 2017

Sylvia Waajen

9

1 reference

26 July 2017

Li Xin Zhang

10

1 reference

26 July 2017

Li Yan

11

1 reference

26 July 2017

Jin Li

12

1 reference

26 July 2017

publication date

8 July 2013

1 reference

Journal of Hematology & Oncology

26 July 2017

published in

1 reference

26 July 2017

volume

6

1 reference

26 July 2017

page(s)

48

1 reference

Creative Commons Attribution 2.0 Generic

26 July 2017

copyright license

start time

8 July 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716995

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716995

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716995

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716995

Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716995

The mTOR pathway: a new target in cancer therapy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716995

Targeting mTOR globally in cancer: thinking beyond rapamycin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716995

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716995

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716995

Akt-dependent and -independent mechanisms of mTOR regulation in cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716995

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716995

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716995

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1756-8722-6-48

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1756-8722-6-48

21 January 2018

Identifiers

DOI

10.1186/1756-8722-6-48

1 reference

Dimensions Publication ID

26 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1756-8722-6-48

9 September 2019

1 reference

26 July 2017

1 reference